Silence Therapeutics PLC

자세한 내용은 Silence Therapeutics PLC 회사

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.

회사 정보

종목 코드 SLN

회사 이름Silence Therapeutics PLC

상장일Jan 05, 2010

CEOMr. Craig A. Tooman

직원 수116

유형Depository Receipt

회계 연도 종료Jan 05

주소72 Hammersmith Road

도시LONDON

증권 거래소NASDAQ Global Market Consolidated

국가United Kingdom

우편 번호W14 8TH

전화442034576900

웹사이트https://www.silence-therapeutics.com/

종목 코드 SLN

상장일Jan 05, 2010

CEOMr. Craig A. Tooman

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Timothy (Tim) McInerney

Independent Director

--

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

--

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

--

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

--

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

--

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

--

Ms. Gem Hopkins

Head of IR and Corporate Communications

--

Dr. Michael Harvey Davidson, M.D.

Non-Executive Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Timothy (Tim) McInerney

Independent Director

--

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

--

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

--

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

--

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

--

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

--

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2024

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q3

FY2023Q2

FY2023Q1

데이터 없음

지역별USD

이름

수익

비율

United Kingdom

43.11M

99.67%

Germany

144.00K

0.33%

USA

0.00

0.00%

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

5.91%

Redmile Group, LLC

4.69%

Morgan Stanley & Co. LLC

4.01%

Other

54.59%

주주

비율

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

5.91%

Redmile Group, LLC

4.69%

Morgan Stanley & Co. LLC

4.01%

Other

54.59%

주주 유형

주주

비율

Individual Investor

24.38%

Investment Advisor

18.47%

Investment Advisor/Hedge Fund

10.53%

Hedge Fund

7.10%

Research Firm

5.08%

Venture Capital

3.35%

Private Equity

2.43%

Other

28.65%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

130

33.69M

71.34%

-14.09M

2025Q1

133

31.94M

67.63%

-14.00M

2024Q4

128

31.43M

66.56%

-10.23M

2024Q3

111

35.93M

77.05%

-5.19M

2024Q2

96

34.94M

74.95%

-4.57M

2024Q1

86

35.43M

76.18%

+4.14M

2023Q4

61

30.21M

78.15%

-609.51K

2023Q3

58

32.62M

88.08%

+1.55M

2023Q2

54

31.78M

89.08%

+2.79M

2023Q1

52

31.17M

88.54%

+2.74M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Griffiths (Richard Ian)

11.51M

24.38%

+543.58K

+4.95%

Jun 25, 2025

TCG Crossover Management, LLC

3.03M

6.42%

--

Mar 31, 2025

Invus Public Equities Advisors, LLC

2.79M

5.91%

-41.94K

-1.48%

Mar 31, 2025

Redmile Group, LLC

2.21M

4.69%

-184.37K

-7.68%

Mar 31, 2025

Morgan Stanley & Co. LLC

1.90M

4.01%

+333.48K

+21.34%

Mar 31, 2025

Lombard Odier Asset Management (USA) Corp.

1.85M

3.92%

-6.29K

-0.34%

Mar 31, 2025

Frazier Life Sciences Management, L.P.

1.15M

2.43%

--

Mar 31, 2025

Vivo Capital, LLC

1.11M

2.34%

--

Mar 31, 2025

Nantahala Capital Management, LLC

1.04M

2.21%

-7.25K

-0.69%

Mar 31, 2025

Nextech Invest, Ltd.

952.40K

2.02%

--

Mar 31, 2025

5.910USD

Silence Therapeutics PLC

5.910

개요

회사

금융